Frontage Holdings Corporation ( “Frontage” or “Company”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both North America and China, announced that Frontage Laboratories, Inc. (“Frontage Labs”), a wholly-owned subsidiary of the Frontage, entered into an equity purchase agreement with third party individuals. According to the agreement, Frontage Labs purchased the entire equity interest in Biotranex, LLC (“Biotranex”). Biotranex, an innovative biotech service company located in New Jersey, USA, is principally engaged in providing a broad spectrum of drug metabolism and pharmacokinetic studies for pharmaceutical and biotechnology companies.
Read the full article: Frontage Expands Drug Metabolism & Pharmacokinetic (DMPK) Services by Acquiring Biotranex //
Source: https://www.frontagelab.com/about/news-item/frontage-acquires-biotranex